<SEC-DOCUMENT>0001193125-14-442643.txt : 20141215
<SEC-HEADER>0001193125-14-442643.hdr.sgml : 20141215
<ACCEPTANCE-DATETIME>20141215163029
ACCESSION NUMBER:		0001193125-14-442643
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141211
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141215
DATE AS OF CHANGE:		20141215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS, INC.
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16133
		FILM NUMBER:		141286850

	BUSINESS ADDRESS:	
		STREET 1:		1301 AVENUE OF THE AMERICAS
		STREET 2:		43RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		(212) 489-2100

	MAIL ADDRESS:	
		STREET 1:		1301 AVENUE OF THE AMERICAS
		STREET 2:		43RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DELCATH SYSTEMS INC
		DATE OF NAME CHANGE:	19990607
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d838196d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of report (Date of earliest event reported): December&nbsp;15, 2014 (December 11, 2014) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DELCATH SYSTEMS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-16133</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>06-1245881</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1301 Avenue of the Americas, 43rd Floor, New York, NY 10019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(212) 489-2100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NONE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item 5.02(e) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Delcath Systems, Inc. (the &#147;Company&#148;) has announced the appointment of Dr.&nbsp;Dennis&nbsp;H. Langer, William D. Rueckert and Dr.&nbsp;Marco Taglietti to the Company&#146;s Board of Directors (the
&#147;Board&#148;). Dr.&nbsp;Langer will serve as a Class III director with his term expiring at the 2015 annual meeting; and Mr.&nbsp;Rueckert and Dr.&nbsp;Taglietti will both serve as Class I directors with terms expiring at the 2016 annual
meeting. Concurrent with these additions, the Company also announced the resignations from the Board of Laura A. Brege, Tasos&nbsp;G.&nbsp;Konidaris, and Gabriel Leung. All changes were effective as of December&nbsp;11, 2014. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Board has determined that Mr.&nbsp;Rueckert is an independent director and a financial expert and has appointed him to serve on the Audit and Nominating and Corporate Governance Committees of the Board.
Dr.&nbsp;Taglietti has been determined by the Board to be an independent director and has been appointed to the Compensation and Stock Option Committee and the Nominating and Corporate Governance Committee of the Board. Dr.&nbsp;Langer has been
determined by the Board to be an independent director and a financial expert and has been appointed to the Audit and Compensation and Stock Option Committees of the Board. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In addition, on December&nbsp;11, 2014, Messrs. Rueckert, Taglietti and Langer each received an option to purchase 30,000 shares of Company common stock under the Company&#146;s 2009 Stock Incentive Plan (the
&#147;Plan&#148;), vesting over three years, at an exercise price per share equal to the Fair Market Value thereof on the grant date, as determined in accordance with the Plan. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Finally, the Board announced that William Rueckert has been appointed to serve as the Chair of the Audit Committee and Harold Koplewicz has been appointed to serve as the Chair of the Nominating and Corporate Governance
Committee. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;15, 2014, the Company issued a press release announcing the changes in Board composition, a copy of which
release is filed as Exhibit 99.1 to this Form 8-K. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following exhibit is filed herewith: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Delcath Systems, Inc., dated December 15, 2014</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">DELCATH SYSTEMS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: December&nbsp;15, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Peter J. Graham</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Peter J. Graham</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Executive Vice President, General Counsel</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Delcath Systems, Inc., dated December 15, 2014</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d838196dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838196g25p73.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DELCATH STRENGTHENS BOARD OF DIRECTORS WITH NEW APPOINTMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Industry Veterans Add Clinical Trial, Financial, and Drug Development Expertise </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New York, NY &#150; December&nbsp;15, 2014</B> &#150; Delcath Systems, Inc. (NASDAQ: DCTH) today announced the appointment of Dr.&nbsp;Dennis&nbsp;H.
Langer, William D. Rueckert and Dr.&nbsp;Marco Taglietti to the Company&#146;s Board of Directors. Dr.&nbsp;Langer will serve as a Class III director with his term expiring at the 2015 annual meeting; and Mr.&nbsp;Rueckert and Dr.&nbsp;Taglietti
will both serve as Class I directors with terms expiring at the 2016 annual meeting. Concurrent with these additions, the Company also announced the resignations from the Board of Laura A. Brege, Tasos&nbsp;G.&nbsp;Konidaris, and Gabriel Leung. All
changes were effective as of December&nbsp;11, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The new directors are all distinguished business professionals who bring a wealth of experience in
clinical trials, finance, and drug development to the Delcath Board. Dr.&nbsp;Langer possesses extensive operating experience in pharmaceutical and biotechnology companies, and has been the CEO or co-founder of several healthcare companies.
Mr.&nbsp;Rueckert has served on public or private corporate boards for several companies in the life science and banking industries, and has extensive expertise in investment banking and corporate finance. Dr.&nbsp;Taglietti has more than 20 years
of experience in senior leadership positions in pharmaceutical research and development, and over the course of his career has successfully brought 35 different healthcare products to market in the U.S. and internationally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commenting on the announcements, Dr.&nbsp;Roger&nbsp;G. Stoll, Executive Chairman and Director of Delcath, said, &#147;I am pleased to welcome Dennis, William
and Marco to the Delcath Board. Their operational, financial and drug development expertise will provide invaluable insights and strategic guidance through the next phases of our clinical development program. I also want to thank Laura, Tasos and
Gabe for their many contributions, guidance and leadership over the years. On behalf of the Board, we wish them well in their future endeavors.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Dennis&nbsp;H. Langer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dennis H. Langer, M.D.,
J.D. has served as a Director of several specialty pharmaceutical, biotechnology and diagnostic companies, and has been CEO and/or co-founder of several health care companies. From 2005 to 2010, Dr.&nbsp;Langer served as a Managing Partner of
Phoenix IP Ventures, a private equity/venture capital firm specializing in life sciences. Previously, he was President, North America, of Dr.&nbsp;Reddy&#146;s Laboratories, Limited. From September 1994 until January 2004, Dr.&nbsp;Langer held
several high-level positions at GlaxoSmithKline plc, and its predecessor, SmithKline Beecham, including most recently as a Senior Vice President of Research and Development. Prior to SmithKline Beecham, Dr.&nbsp;Langer was President and CEO of Neose
Technologies, Inc., and before that held R&amp;D and marketing positions at Eli Lilly, Abbott and Searle.&nbsp;At the beginning of his career, he was a Chief Resident at Yale University School of Medicine, and held clinical fellowships at Harvard
Medical School and the National Institutes of Health. Dr.&nbsp;Langer serves as a Director of Myriad Genetics, Inc. and Dicerna Pharmaceuticals, Inc. Previously, Dr.&nbsp;Langer served as a Director of Ception Therapeutics, Inc. (acquired by
Cephalon, Inc.), Cytogen Corporation (acquired by EUSA Pharma Inc.), Pharmacopeia, Inc. (acquired by Ligand Pharmaceuticals, Inc.), Sirna Therapeutics, Inc. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(acquired by Merck and Co., Inc.), and Transkaryotic Therapies, Inc. (acquired by Shire plc).&nbsp;Dr.&nbsp;Langer is a Clinical Professor in the Department of Psychiatry, Georgetown University
School of Medicine.&nbsp;Dr. Langer received a J.D. from Harvard Law School, an MD from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>William D. Rueckert </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Rueckert has served on many
public and private corporate boards in both the life science and banking industries. He is currently President of Oyster Management Group, LLC, an investment partnership specializing in community banking. From 2007 until 2012 he served on the board
of Novogen Ltd. (ASX, NASDAQ) a biotechnology company based in Sydney, Australia. He acted as Chairman from 2010 until 2012, and as acting CEO led the restructuring of the company, spinning off its major subsidiary, Marshall Edwards, Inc. (now MEI
Pharma, Inc. NASDAQ.) He is currently a director of MEI Pharma, Inc. (NASDAQ), a San Diego based company that is developing novel oncology therapies. Until its sale to H. Lundbeck A/S, he was a director of Chelsea Therapeutics International, Ltd.
(NASDAQ) whose drug candidate, Northera, was approved by the FDA in 2014. He has also served on the boards of several banks including Westport Bank and Trust, Lafayette American Bank and Hudson United Bank (all NASDAQ.) He currently serves on the
board of Fairfield County Bank, a mutually owned, community bank based in Ridgefield, Connecticut. Among his civic associations, Mr.&nbsp;Rueckert is a Director and President of the Cleveland H. Dodge Foundation, Co-Chairman of the Board of Trustees
of Teachers College, Columbia University, a Director of the Y Retirement Fund, a Trustee of International House, an Emeritus Director of the YMCA of Greater New York and a Director of Wave Hill, Inc. He earned a BA in Spanish in 1977 from the
University of New Hampshire. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Marco Taglietti </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Taglietti serves on the Board of Directors of NASDAQ-listed SCYNEXIS, Inc., a pharmaceutical company committed to the discovery, development and
commercialization of novel anti-infectives; and NephroGenex, Inc., a pharmaceutical company focused on the development of therapeutics to treat kidney disease. Prior to its recent acquisition, Dr.&nbsp;Taglietti served as Executive Vice President,
Research and Development, and Chief Medical Officer of Forest Laboratories. He also served as President of the Forest Research Institute. Prior to joining Forest Labs in 2007, Dr.&nbsp;Taglietti held the position of Senior Vice President, Head of
Global Research and Development, at Stiefel Laboratories, Inc. for three years. He joined Stiefel after 12 years at Schering-Plough Corporation where he last held the position of Vice President, Worldwide Clinical Research for Anti-Infectives,
Oncology, CNS, Endocrinology and Dermatology. Dr.&nbsp;Taglietti began his career at Marion Merrell Dow Research Institute. He received his medical degree and board certifications from the University of Pavia in Italy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Delcath Systems </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delcath Systems, Inc. is a
specialty pharmaceutical and medical device company focused on oncology. Our proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)-is designed to administer high dose chemotherapy
to the liver, while controlling the systemic exposure to those agents. The Company&#146;s&nbsp;principal focus is on the treatment of primary and metastatic liver cancers. In the United States, the Melphalan/HDS system is considered a combination
drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA).&nbsp;The Melphalan/HDS system has not been approved for sale in the United States. In Europe, our proprietary system to deliver and filter
melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Delivery System for </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Melphalan (CHEMOSAT). In April 2012, we obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT&nbsp;system.&nbsp;The right to affix the CE mark allows the Company to market and
sell the CHEMOSAT system in Europe. The Company has commenced a Global Phase 2 clinical trial in Europe and the United States to investigate Melphalan/HDS system for primary liver cancer and is initiating plans to evaluate intrahepatic
cholangiocarcinoma, and is initiating a Phase 3 trial in ocular melanoma liver metastases in 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Private Securities Litigation Reform Act of 1995
provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the timing and results of the Company&#146;s clinical trials including without limitation the HCC, ICC, and OM
clinical trial programs, timely enrollment and treatment of patients in the Global Phase 2 HCC and ICC clinical trial, FDA approval of the Global Phase 3 OM clinical trial protocol, IRB or ethics committee clearance of the Phase 2 HCC/ICC and/or
Phase 3 OM protocols from participating sites and the timing of site activation and subject enrollment in each trial, the impact of the presentations at ESSO and future clinical results consistent with the data presented, approval of Individual
Funding Requests for reimbursement of the CHEMOSAT procedure, the impact, if any of Value 4 status on potential CHEMOSAT product use and sales in Germany, clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and
filter melphalan in Europe including the key markets of Germany and the UK, the Company&#146;s ability to successfully commercialize the Melphalan HDS/ CHEMOSAT system and the potential of the Melphalan HDS/CHEMOSAT system as a treatment for
patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets, the Company&#146;s ability to satisfy the requirements of the FDA&#146;s Complete Response Letter and provide
the same in a timely manner, approval of the current or future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the US and/or in foreign markets, actions by the FDA or
other foreign regulatory agencies, the Company&#146;s ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same, uncertainties relating to the timing and
results of research and development projects, our ability to maintain NASDAQ listing, and uncertainties regarding the Company&#146;s ability to obtain financial and other resources for any research, development, clinical trials and commercialization
activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are
made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Contact Information:</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&nbsp;Contact:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Media Contact:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Michael&nbsp;Polyviou/Doug&nbsp;Sherk</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">John Carter</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EVC Group</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">EVC Group</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">212-850-6020</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">212-850-6021</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g838196g25p73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838196g25p73.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``,"`@,"`@,#`P,$`P,$!0@%!00$
M!0H'!P8(#`H,#`L*"PL-#A(0#0X1#@L+$!80$1,4%145#`\7&!84&!(4%13_
MVP!#`0,$!`4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P``1"`!+`/H#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]+O'.M3>'
M/!FOZK;!&NK'3[BZB60?+N2-F7=[96OS%@_X*A?%YHU=M.\*<_\`4.N/_DBO
MTH^,MR+3X0>-YRZILT.];<W_`%P>OP>MH6=8HE^^VQ:^ER;#4:ZG[6!X.95Z
ME&4.21]>?\/0/B[_`-`_PE_X`3__`"174^!O^"I_BRROHD\8>$=+U+3_`/EJ
M^CN\%PO^ZKNZO_X[7V3!^R5\'+G2HH9OAOX=W/`JL_V)5?[O]_[U?FG^VM^S
M]IO[/WQ7MK+07=O#VLV?VRTBD;<T!W['BW?Q?P[?]^NG#2R['3]C[$QK1QF'
MAS\Y^L/PM^*/A[XP^#+#Q-X8O1>Z5<\`E=K1NOWHW7^%E]*[/U-?FO\`\$JO
M&MW#XQ\:^$7D8Z?<V,6JQ1/_``2H_E/_`-]*R?\`?%>A?M;?M_3_``Q\4WW@
MKX?6UK=ZU9_NM0U6^7=#:R_\\HE_C=?XMWRK7C5<MJ?6I8>D>G2Q<?8>UF?<
MH//(I6-?D,O[3/[3^H^&Y_&$.K^(&\-QMYDFHV^BV_V)?X<[O*^Y7MO[*_\`
MP4)UWQ7XTTGP=\2([2<ZG*MK::];0^0ZSM]Q94^YM;[H==M74RFO"'/'WB*>
M84IRY#V']N/]IGQ9^S?8^$)?"UKI=Q+JTMTD_P#:4#R[5C1"NT*Z_P!^N-_8
MO_;!^('[0_Q0U/0?$=GH<&EV6DM>EM.MI8I3)YL2*-SRO_?>N)_X*P7.^]^&
MEK_$D>H2_K;US_\`P2HL2?B9XZO#]R+2(8?^^YMW_LM=JPU'^R_;<OO?_;'+
M*O5^O>RYO=/TR7`-#&OA[]L']O&[^%7B2?P3X!AM;G7[7C4-4NU\V&S9EW"-
M$'WGX^;=]W-?'TW[<GQSFNVF_P"$_NDD;YA%%96NW_OGRJXJ&4XC$PY_A.JK
MF%*C/D/VCX]:!@5\??\`!/C]H+QE\=-$\8KXRU.#5;G29[5+:9+9(7V2(Y;<
M%]TK@/VE/VK_`(S6/QO\0>`_A9IOVVWTCR(WFL-(:]N&E>)7?<?F5?O_`-RN
M?ZA65>=#K$V^MT_9>U/OM0W]W]:?@=Z_)GQ]\9_VM/AYIRZWXIO]?\/Z;+(L
M:W$NG6BQ*Q^ZO^J^7_@=>L_L>_MU^,_'WQ+TWP-X\>TU1-5WQVFI0VZ6\L<J
MHS;65/E96V=0M=%;*:L:7MHSC+T,J>/IRER3CRGW#\1OB/X>^%GA&\\2>)KX
M:=H]IL$UP8G?9N;:ORJ"WWC7B7P]_;Q\"?%;XI:1X'\*Z?K-]<:CYA_M">W6
M"W5$B9]WS/O_`(/[M?(G[?/Q_P#&FI_$_P`8_#235(&\%P36KK9+:IOW+%%+
M_K?O??KYF^'?Q$U[X4^+[+Q/X:N8[/6K-62":6!947<FU_E;Y?NO7?ALFC.A
MSR^*1R5LPE"KR1^$_</XE^(YO!OPY\3Z];(C7>F:9=7L2RC<K/%$SKN_[YK\
MU=/_`."FOQ@O;JUMDTOPH'N)4B7_`(EUQ]YF_P"OBOH/X0_&;Q7\6/V'?BAX
MH\8W\&HZJMKJT$4R6RVZ+$MJNU=B_P"TS5^9WAB_@TKQ'H]]>+)-:6MY;W$J
M0_?95='=$K?+,%3?MHUH<THDX[$R]R=*1_0##N\I?,^]M^:I#]*_'_Q__P`%
M"?B_XNUZXFT?78_"NE>9BVL+&UB=PO\`#OEE1F9JZ'X)?\%$?B1X9\7Z;!XW
MU-?%'AN>=(KPRVL45Q`C/M\U6B1?N_W6KS99+BU#G.O^TJ'-R'ZP45&DBS(K
M+\R-4E>&>J%(:SM7UNQT*V\^^N8[6+^\]<?-\9]$27;''=S+_?2*KC3E/X2.
M8]`!%.KEO#_Q!T3Q)*L%M<[+AO\`EWG78[?A749XK-QE#XBQ:***8!1110!Y
MA^TI>_8?V>_B-.@^9-!O0/KY+K7XC>&X?M/B/1X/^>MY`G_D5*_97]M;41I'
M[*_Q$F#?>T[R?^_DJ)_[-7XQ6E_+IM[;WD#;+BWE26)_[K*^Y*^QR&/[B9\U
MFG\2!_04BF-%7H*_*+_@I1\1]/\`&OQTLM&TR99X?#>GFSN94;Y?M3OO=/\`
M@"[?_'Z\XU[]MCXV>(=/EL[GQ[>0P2_>-C;V]N__`'VJ(Z_\`KE?AA\!/B#\
M:=5BA\,^';V^25_WNIW"/%:1?WV:5OE_]GHP.6_49_6,1,G$XWZW#V5*)]%?
M\$RM,N[+QI\0?%2QM);Z5H/V<MGY7D=_,1?^^8&KXYU+59]>O[O4+R5IKN\E
M:XGE=_ONS[W_`/0Z_:C]FW]GC2OV?_AC#X9@==0OKIO/U2^*;3=3LNUO^`*N
M%7V%?EG^TI^S9XC^`GC;4[:XTVYF\*SSLVFZNL6^"2-F^1';^!T^[M:M<#BZ
M6(Q=5]R<3AI4J$#W>Q\;?M:1_#Z'PI:_#QO^$:;3?[-BMXM&BV?9O*V?W_[M
M>(>&_P!E#XRV'B#1Y_\`A76N6WD7D#^<\:?NMKI\_P!^NW^&7_!1GXD_#OPM
M:Z%)!H_B."SB6WMKG4U?[0JK]Q7977?7O/['?[5_Q._:/^.SV&L7>G6?ANPT
MR>\GT_3+/8K-N1$W.S.WWG/\7\-$I8K!QG/V,.4(^PQ$H0YYG$_\%6K_`'_$
MCP'9_P#/+2KB7_ON7;_[+6W_`,$G+/???$J[V_=CL(E?;_U\5P7_``5%U9;K
MX_:):?\`/GH$7_C]Q+7J?_!)V!?^$=^(]P.=U]9Q;O\`=BE_^*K"?NY,OZ^T
M:Q][,3X%\?ZQ<Z]XV\2ZK>,TUU>:C=7$KO\`Q,TKU^PO[*?PA\(^`?@GX3.D
M:79S76HZ9!>7E^\"M+<RRQ*S%V_X%]VOSB_;(_9SU[X-?$_6]533YYO!NK7D
MMY8ZG"N^*+S7WM!+_=96W?[]8OPS_;2^*GPD\+0^'="\16TFD6Z[;6'4;:*X
M^SK_`'5;[VW_`&:Z\70GF.%A]7F<V&JQPE>?M3]@8]'\,>!K;6-<CT_3M#A,
M7GZA>Q0I#N2+<V^1E'.WY^3ZU\)_$S_@J$EAJ-W;?#?PE;/:EV_XFNL;U$[?
M\]/LZ[6_[Z85VWP9N_B%^U!^QC\2)]9UI]5\1Z]+=6NF!H4@15C1`D2[=J[6
M=7_[[K\X]-FE\#>,K)M9T59KC2[Y&O-&U--GF^4_SQ2I_P".UYN7Y?2G*K'$
M>]*!V8O%SA&'LO=C(]6^,'[0'Q@^/?A)[OQ.;EO!MK<*[?8=.\C3TE_Y9;G_
M`(F_N[GJS^PU9F__`&J_`"!?EBGN)6_X#:RUTG[27[;MW^T#X#M_"&G>$;7P
MSX?@GBN)=MU]H?=%]Q5VJJJO_`:J_P#!.Z))_P!JWPU_TRM+YO\`R`U>TU.G
M@I\U/D^(X8\D\5#W^<^J?^"IDUO:_!KP["L:+/<Z\C[E7YFVV\W_`,57S)_P
M3?L(;[]INS,T:RK%I-Z^UUW?W%_]GKZ<_P""HOA/4];^$OAO5["WDN;/1]3>
M6^$2[O+22)D5V']W<<?\"K\Z_AA\6=>^#GBZU\4^%M0CL]5@1X=\L:RJR/\`
M?1E:N++Z?MLN]E#^\=&+E[+&<\C]A/VMI8-"_9@^(TD:QVT7]CS)\B[?O_+_
M`.S5^,_A709_%7BC1]#@;9<:E>062/\`W'E=$_\`9Z_0_P`<_$_Q+XY_X)MZ
M[XJ\8WL5UJVO,JQ-#`L2+$]\D42[%_V5_6OBC]F&V6__`&COAK`VW9_;]J__
M`'S+O_\`9*651EAZ%9_RACI1K5:1^F_Q'_9<^&GAO]G3Q1H-EX4TY$T[1;BX
MBOA;I]J\^*)F27S?O;MR^M?D'IJ?:;VRB_YZRQ)_WT]?N%^TGJ(T?X`?$2Y+
M;=N@WB;O3="Z_P#LU?B5X,A6Y\6^'X';9YNHVJ_^14IY'4E*G6E.89E&,)0A
M$_?BTB%M:PQ?W45:S_$WB"#PSI%Q?3X;;\J)_>?^%:Y?Q/\`%:S\+>/=%\+R
MZ?<33:IMQ<1LNR+<Q1<_]\FN8^*=]-XB\766B6SX$6U=O_35O_L*^1ITY3E[
MQ]%SF)9Z;K7Q-UN6X9\(OWI7_P!5`O\`<2N\M?@CI"1?O[N\EE_OJR+_`.RU
M-XCURU^&'ANUTW3T62\=?W6__P`?E>O-D/BWQ+NO8O[1NU_YZQ.R)_P"NKWY
M_![D#/W(&[XI^$EWHD+W>FSO?11?,R%?WJ__`!5=#\+_`!^VK#^R=1DWWB+F
M&9_^6B_W6_VJQO`GQ)OK'4DTO6Y&FB9_*6:7[\3?[=5OB1H3^$?$EKJ^G_N8
MI7\U=G\$J_>_[[I<LI_N:H?WX'N%%4M*OXM6TZUNX_N3QK(M7:\\Z0HHHH`Q
M=2O])N(Y;2]DMYACYX9EWK_WS69]D\'_`//AI/\`X"I_\34UYI>KR7DK0R6`
MB9OEWQ?/47]BZY_SUTW_`+]M6L>7^8@3[)X1_P"?#2?_``&3_P")K637=+@7
M8EU"JK_"M9?]C:W_`'],_P"_;4?V-KG_`#UTW_OTU'+`#6_X2'3?^?V+\ZAN
MM6TF\MW@GN+>:)QM9)/F5JSO[%US_GIIW_?O_P"QH_L;7/\`GII?_?IJ7+`#
M!E^&7PJN)_.D\(^%7E_OOI4'_P`16]HD'A7PO;M%I%MI>EPM_#8PI$I_[XI?
M[%US_GIIO_?IJ/[%US_GIIO_`'Z:KTE]HGD)K[_A&]0F$UW'I]S-]W=-&KM4
MEA<Z!I2L+$V5FK?,WV=%3=^54_[#UO\`YZZ;_P!^VI?[&UO^_IW_`'YJ>6/\
MQ1HW>JZ-J%NT%S<6]Q;RKM:*1=RM7'_\*R^%1N?/_P"$1\*^;_?_`+*@_P#B
M*WAHVM_\]-._[\FE.BZY_P`]--_[]-5)*/PR#XB]8:AHFF6:6UI+:6L"?=BB
M78J_\!K"U[PSX`\73K-KVBZ%J\__`#VU&QBE;_OIUJ__`&-K?_/33O\`OR:/
M[&US_GKIO_?IZGW/Y@*^G:#X(T>Q:TL=+T6QM&;<UO;VD2(S?[FVKEFGAG3I
MC/:PZ;;3?WH841ZC_L;7/^>NF_\`?IZ/[&US_GKIO_?IZ/<_F`U)M;TJYB:.
M6ZA>)OE97^ZU<;_PK3X6?:?M'_"(^%_/_O\`]E09_P#0*W?[&US_`)Z:9_WZ
M:E.BZY_STTW_`+]-5)*/PR'\18>;P\]BMDRV+V2_=@\M?*7_`(#4$$/A2UG6
M2"UTN"5?F5T@1'7_`,=H_L;7/^>NF_\`?IJ/[&US_GKIO_?IJCW1&A=:SI%Y
M`\$]Q;RQ-\K))\RM7%:CKFA:?>;+'PE;7FSI+Y$47_?/RUTAT77/^>FG?]^O
M_L:Y+6O$GB+0KQX9/#\MRG\,MI:^:K?]\UI3C%DS.MTKQ-I6MF.YNH%L[R'[
MOVM5W+_NM7!>$X_/^(]]JM\ODV^Z66)Y5^]_`G_CM=/H+>(M;M?.ET^VTI?X
M4NXOG;_@-9>A>*-0UW7;G2XXK2VN+??\TJ?*^U]M7&/+S\H&-K5L?%GQ&WW@
M9-+1MOF_P>4O_P`778:[\2+#PS)!;0V,EQ:JJHTMO\J1_P"RM8L/BN^?Q2^@
MM%:0S^:\7G,GR._WZ9XX@\1/;_V6FE+=I/M_TBUB^3_[&KY>:4(S`3XM:5::
MCH]EXBM-I$NQ6=?XD?[C58\1N?$?P@M;V3#SP)$^[_;5]C?UH\=Q#P_\,-/T
MJ9U>Y8Q1?\"7YF_E3-OV'X'N)/\`EJGR_P#`I:</@A_B`UOAEXCM(?!UK'<W
M*0O$S+M?^[NIUY\3FAN?+@T2ZN(?^>K.JG_OFL?X<Z;JD_A:*2T>T\II)=JW
M"?-5:_\`%OB*PO7MI?#5R[_WXK;S4;_@2TN2$IR%S>Z>A:=XOT_4+596E^S/
M_%#-\K+5O_A(=-_Y_(OSKFM*M/$.HV:33V]E8NW_`"QE3YU_[YJ[_8NM?W].
M_P"_7_V-<W+$LPOC[XFU_P`&_"?7M7\-QLVJ6HB?S4M?M301>:HEG6+_`):M
M''O?;WV5/\+=*=-)CUJU^(.I>.M(U."*6VN+[[*T6/[T3011?>S_`!;JWO&'
MB.;PGH[ZA%HNIZ\RR*K6FDQ+)/M8_>VLR[MM>4?!O1[ZV^+'BW4=!\/ZKX3\
M`:A;1RMIVJP?95GU;S7\VX@M_O1*T6W=G9N;YMO\1R+/4/$?CK3_``KK_AK2
M+];A'\07,ME:7"IF)9DB>78[_P`.Y4?;_NT)X[TY_B`WA&-9Y=4BTQ=5G94_
M<P1--Y2*S]F=EDVK_P!,FKF/VB-$DU3X4ZK?VLD4&JZ`4U_3II7V*EQ9MYZ9
M;^ZZHR-_LNU5O@#IMWJ7AW4/'6JVKV>M>,ITU5[:8?O;2UV[;2W;W2';N_VW
MDH`Z3QY\2K7P)<Z'8-I]_K6KZU<-;:=IFF(GG3LB-*[;I'1%553+%F%=!H6I
MRZOI5O=SZ==Z7+*F]K.]V>=%_LOL9E_\>KSGX[6&E:OI-C8:KH/B2^F5VN].
MU7PU;/+=:;<I]V5&3YHW^;C^%OF5_ESGIOA#/XHNOAIX=F\90K;>*6M%.H1*
M5XEY^]M^7=]W=MXW;L4`<SIGQFU"]^-'B'P3_P`(CJ\MGI=O9N=6@2$1+Y_G
M?._[T-Y?[KY=J,WWJ[_Q5XITWP7X=O\`6]8N5LM,L8GGGN&SA5P>W\3>U>:>
M'YM1\-?M$^-Y+S0M4?3M?M=+2QU>WMO-M?W$5QYJ2R#_`%>UF_B_OUL?M%^!
M-1^(_P`(M;T72X([R_=[6ZBL99?*2\\BXBG\AG_AW^5LW=MU`$ND?&*&\UO1
MM-U?PWK_`(6DUO<NF2ZQ!$J73JN_R?W4KM%)L5VVRA?N-73^/O&FG?#?P3K?
MBG55E_LW1K.6]N?LZ;W\M%W-M7OTKR7X>>%_`NL>)M'NK?X:>)=&U2R+7L5Q
MK<,_E6,ZIM^^TK(S_,R_)NKL_P!HS0M1\3?!'Q?I&DV4VI7U_9&V6T@^_*'9
M58#_`(#NH`Y^X_:<T33+O2$O?#GB>R@UX,-"N)M/7&K2[=RQ1*KET=D^=?-5
M,J'Z;:Z[P%\4[3QWJ^N:*^DZKX>US1_*:YT_58D5_*EW^5*K1,Z,K;&^ZW\-
M9/Q$\/ZAJ?Q2^$D]E8R76E:7J5]/>3)]RW_XE\\43-_P)]OXU-X2T'4(OCA\
M0]7NK&:"QN;'2;6SNG^Y<");AWV_[K2T`:_C_P"(]G\/6T2W>POM6U/6;PV6
MGZ9IZ(TT\HB>1OF=T555$9F9FK?\/:M/K&D6]Y<:7=Z1+*&+6=]L\V/YOXMC
M.O\`X]7!_'&TT76-&M-.UO0/$6JPM*;BUO?#EL\MUI]U'CRI4=/FB?YCL?[O
MWMV!5/PC\1]9\'_#KP&GCVQO)O&.O7B:7]EM(HC</*V]EEE1&V)^Z3S9=GRI
M\]`'L%%%%`'F/QK\6:MX2LO!QTFX-M/J/BK3-,GQ$K[[>67]\OS?[`;YJ]+>
M38K-_=KRWXWZ#J7B*\^'"Z?83WD=IXOL[V\DB_Y=[>.*X?S6_P!G?L7_`('7
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M<R_NU_B^O2@#=VUXCK,O_"%_%?[6QV6LLOFL?]F3[]>WBN`^*OA)_$&E)>6J
M;[VSYV+_`,M8OXTK:@US>\3(P/BWX<GMK^+Q%8E]OR^:T7\#+]QZETKXV1)9
M(FH:?(]TJ_>MV78__P`34/P\^(ULEDNC:VZB)1LCN)/N[?[K5TLWPJ\-:BPN
M(8Y$C?YO]'F^1JWERP]RJ9_WH'G%[J&H_%/Q-;PJODPI]U5^[!%_$SUTOQ>U
M&#3M)TW0+8?*FUF7^ZB_*M=#>ZWX>^&FFM!:11_:F^[;Q-N=V_VFKAO!FE7?
MCOQ6^K:A\]O#+YLK_P`#-_#$M:1E?W_LQ)/5/!.E'1?#&FVK#]ZL6Y_]YOF-
M=`1FEHKS9>\=`4444P"BBB@#S_XA_"^S^)J1VVJ:SJT6B?(EYHMM.D5K?HK[
MMDXV[]O9E5UW+\K9%=XB*B[57Y:DHH`****`"BBB@`HHHH`****`"J[6L4TD
M<KQJ\D?W79?F6K%%`!1110`4444`%%%%`!1110`4444`>:>,_A/%K$SWVERK
M:7;?,T3C]T__`,37"/\`#[Q98/Y4=E<[?^G>?Y/_`$.OH.BNB&)G'W49^SB>
M)>'_`(.:E?3I+JC+8P?Q*C;I7_&O8=*TJTT2PBL[.%8+=/NHM7L"EJ*E65;X
/AQCRA1116184444`?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
